Profound Medical (Profound Medical) Debt-to-Equity : 0.26 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Profound Medical Debt-to-Equity?

Profound Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.36 Mil. Profound Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.58 Mil. Profound Medical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $31.18 Mil. Profound Medical's debt to equity for the quarter that ended in Dec. 2023 was 0.25.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Profound Medical's Debt-to-Equity or its related term are showing as below:

PROF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.36 Max: 0.76
Current: 0.26

During the past 10 years, the highest Debt-to-Equity Ratio of Profound Medical was 0.76. The lowest was 0.02. And the median was 0.36.

PROF's Debt-to-Equity is ranked worse than
55.15% of 709 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs PROF: 0.26

Profound Medical Debt-to-Equity Historical Data

The historical data trend for Profound Medical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Profound Medical Debt-to-Equity Chart

Profound Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.76

0.02

0.16

0.26

Profound Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.16	0.17	0.19	0.21	0.26

Competitive Comparison of Profound Medical's Debt-to-Equity

For the Medical Devices subindustry, Profound Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Profound Medical's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Profound Medical's Debt-to-Equity falls into.

Profound Medical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Profound Medical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.363	+	5.578)	/	31.18
	=	0.25

Profound Medical's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.363	+	5.578)	/	31.18
	=	0.25

Profound Medical (NAS:PROF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Profound Medical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Profound Medical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Profound Medical (Profound Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Profound Medical Corp (NAS:PROF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PRN:Canada

Address

2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5

Website

https://www.profoundmedical.com

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.